CRCI2NA

What CRCI2NA does

CRCI²NA is a French public, non-profit joint research unit created in January 2022 by INSERM, CNRS, Nantes Université, and Université d'Angers. It operates across five Nantes- and Angers-area sites with more than 330 members organized into 12 research teams; the center describes itself as the largest cancer research center in France's Grand Ouest region. Its intended beneficiaries include cancer patients reached through clinical translation, while its direct operating constituency includes academic researchers, clinicians, trainees, institutional bodies, and clinical research partners.

CRCI²NA investigates tumors as ecosystems in which malignant, immune, and stromal cells interact and change during progression, dissemination, and treatment response. Its research combines cancer genomics and computational biology with cell and molecular biology, 3D and murine models, immuno-oncology, and advanced imaging. It also works on treatment resistance, extracellular vesicles, chromatin and transcriptional deregulation, targeted radiotherapy through radionuclide delivery, and interventional implants for glioblastoma; the center reports more than 55 active research projects and more than 800 scientific papers.

CRCI²NA does not sell commercial products or services. Its operating model is public research funding through its four supervisory institutions, competitive grants, and foundation support, supplemented by collaborations with Institut de Cancérologie de l'Ouest, CHU de Nantes, and other regional hospitals. Research findings are disseminated through publications, graduate education, seminars, open science activities, and translational research rather than pricing-based sales.

Name

CRCI2NA

Legal name

CRCI²NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers

Website

https://crci2na.univ-nantes.fr

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

CRCI²NA is a French public, non-profit cancer and immunology center serving researchers, clinicians, trainees, and patients through translational research. Its 12 teams combine genomics, cell models, immuno-oncology, imaging, targeted radiotherapy, and immunotherapy, supported by clinical partnerships and graduate training.

Ownership category

akta.pro rank

Product category

Cancer and Immunology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Cancer research
• Immuno-oncology research
• Tumor biology studies
• Academic research institute
• Graduate biomedical training

Headquarters

HQ city

Nantes

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Public Research Funding: As a public research unit under INSERM, CNRS, Nantes Université, and Université d'Angers, CRCI2NA receives institutional funding from its four parent organizations. Additional project-based funding comes from competitive grants (ARC Foundation, Ruban Rose, SIRIC ILIAD, Héma-Next cluster, CNRS, Inserm). The center also benefits from LabEx IGO and receives donations from foundations such as the ARC Foundation. The center has received a 150,000€ Ruban Rose research grant and Guillaume Van Niel received a Connect Talent financing.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

CRCI²NA is a publicly funded joint research unit (UMR INSERM UMR1307 / CNRS UMR6075) that conducts multi-disciplinary cancer and immunology research across 12 teams. Its work covers tumor ecosystem analysis, cancer genomics, cell and molecular biology, 3D and murine models, immuno-oncology, advanced imaging, and the design of innovative loco-regional and immunotherapies. It also delivers graduate training through the OHNU and I³ programs and disseminates research outputs through open-access publications and clinical-translational collaborations.

Product overview

CRCI2NA is a cancer and immunology research center (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), not a product company. It is a research institution created in January 2022 by INSERM, CNRS, Nantes Université, and Université d'Angers. The center comprises 12 research teams exploring tumor ecosystems, combining expertise in cancer genomics, cell biology, immuno-oncology, and imaging. CRCI2NA's non-commercial offerings include two graduate educational programs: GP OHNU (Oncology, Hematology and Nuclear Medicine) and GP I3 (Immunology and Immuno-Intervention), both aimed at training the next generation of researchers in cancer and immunology.

Differentiator

Problem solved

Functional benefit

Products and services

• Graduate Program OHNU (Oncology, Hematology and Nuclear Medicine)

Quantifiable outcome

• 800+ scientific papers published
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core, significant and minor.

• SIRIC ILIADcoreStrategic or Co-development PartnerSIRIC ILIAD is a major clinical research program in integrated oncology. CRCI2NA teams collaborate with SIRIC ILIAD on multiple research projects including triple-negative breast cancer workshops and translational research in oncology and immunotherapy. The partnership supports B-cell lymphoma research (Team 11) and was involved in a workshop on triple-negative breast cancer: A dialog between basic science and clinical practice held March 3, 2025.
• Institut de Cancérologie de l'Ouest (ICO)coreStrategic or Co-development PartnerICO is a major cancer treatment center in the Grand Ouest region. CRCI2NA partners with ICO for translational and clinical research including glioblastoma treatment (Team 5), lymphoma research, and co-organized the triple-negative breast cancer workshop with SIRIC ILIAD in March 2025. ICO also hosted the Mai en Gris (Brain Tumour Awareness Month) event in Angers.
• INSERMcoreStrategic or Co-development PartnerInstitut national de la santé et de la recherche médicale (INSERM) is one of the four institutional tutelles (supervisory bodies) of CRCI2NA, alongside CNRS, Nantes Université, and Université d'Angers. INSERM also supports CRCI2NA's Ecological and Societal Transition (TES) process through its GreenLab unit and provides CSR/accompanying support. The center is formally designated as INSERM UMR1307.
• CNRScoreStrategic or Co-development PartnerCentre National de la Recherche Scientifique (CNRS) is one of the four institutional tutelles of CRCI2NA (INSERM UMR1307/CNRS UMR6075). CNRS researchers are embedded within the center (Teams 6, 7b, 12) and support research through national research infrastructure.
• Nantes UniversitécoreStrategic or Co-development PartnerNantes Université is one of the four institutional tutelles of CRCI2NA and hosts the center's main headquarters at IRSUN. It supports graduate training through the OHNU and I3 Graduate Programs, provides technical platforms, and manages the center's website and communications infrastructure.
• Université d'AngerscoreStrategic or Co-development PartnerUniversité d'Angers is one of the four institutional tutelles of CRCI2NA and hosts the IRIS site of the center. It contributes to research and training activities alongside Nantes Université.
• Josep Carreras Leukaemia Research Institute, BarcelonasignificantStrategic or Co-development PartnerCollaborated with Team 11 (reMoVE-B) on the CAM in ovo model for B-cell lymphoma research, which was featured on the cover of Blood journal (November 2023). This international collaboration made the CAM in ovo model accessible at CRCI2NA for studying aggressive lymphomas and resistance to targeted therapies.
• Héma-Next ClustersignificantStrategic or Co-development PartnerA regional competitiveness cluster that supports the B-cell lymphoma research conducted by Team 11 (reMoVE-B) alongside SIRIC ILIAD, contributing to funding and strategic coordination of hematology research in the Grand Ouest region.
• LabEx IGO (Laboratory of Excellence in Oncology)significantStrategic or Co-development PartnerCRCI2NA members are involved in the management of LabEx IGO training axis, supporting graduate education and research excellence in oncology across partner institutions.
• Triplettes Roses, Jeune et Rose, Europa Donna, AVLCminorGTM or Marketing PartnerPatient advocacy and support groups partnered with SIRIC ILIAD and CRCI2NA for the triple-negative breast cancer workshop on March 3, 2025, aimed at awareness, patient engagement, and dialogue between basic science and clinical practice.
• Gilead and MSD LaboratoriesminorOthersProvided institutional support for the 2nd Workshop on Triple Negative Breast Cancer organized by SIRIC ILIAD in partnership with CRCI2NA and ICO, held March 3, 2025 at Mercure Nantes Centre Grand Hôtel.
• Le Labo des SavoirsminorGTM or Marketing PartnerScience communication partner that co-organized a public conference on cell death (La mort cellulaire, un processus clé pour la vie) with researcher Sophie Barillé-Nion at the Muséum d'Histoire Naturelle de Nantes in October 2024.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Francis Crick Institute: Major biomedical research institute in London with significant cancer biology programs. Comparable as a multi-disciplinary research institution focused on fundamental biomedical discovery with translational pipelines and graduate training programs.
• Gustave Roussy Institute: Leading European cancer center in Villejuif/Paris combining research, treatment, and teaching. Comparable as a comprehensive French oncology institution with multidisciplinary teams, immuno-oncology programs, and clinical trial infrastructure.
• Institut Curie: France's leading cancer research center combining a hospital with a research center in Paris. Comparable as a multi-team, multi-disciplinary oncology and immunology research institution with a strong bench-to-bedside pipeline and translational collaborations.
• German Cancer Research Center (DKFZ): Germany's largest biomedical research institute and leading European cancer research center in Heidelberg. Comparable as a large multi-team cancer research organization with programs in immunology, genomics, cell biology, and translational research.

Regional players

• IRCCS - Istituto Europeo di Oncologia (IEO): European cancer research and treatment institute in Milan, Italy. Comparable as a European cancer research institution with translational oncology, immunotherapy, and clinical research programs in a single regional hub.
• Institut Bergoni\u00e9: Cancer treatment and research center in Bordeaux, similar in scale and regional positioning to CRCI2NA in the French oncology ecosystem. Comparable as a regional cancer research institution with translational programs and clinical research collaborations.

Emerging players

• Vall d'Hebron Institute of Oncology (VHIO): Spanish cancer research center with strong translational and clinical trial programs. Comparable as a European multi-team cancer research institution integrating basic research with clinical translation in oncology and immunotherapy.

Direct peers

• Institut de Canc\u00e9rologie de l'Ouest (ICO): Cancer treatment center in the Grand Ouest region of France that is a core translational partner of CRCI2NA. Comparable as a regional clinical oncology partner and collaborator on glioblastoma, lymphoma, and breast cancer research.
• Centre L\u00e9on B\u00e9rard: CLCC (Cancer Center) in Lyon focused on cancer research and treatment. Comparable as a regional French cancer research and care institution with translational research teams, clinical trials, and academic partnerships.

Others

• SIRIC ILIAD: Integrated oncology research program in the Grand Ouest region. Comparable as a translational oncology program partner collaborating with CRCI2NA on breast cancer, lymphoma research, and clinical translation workshops.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crci2na

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRCI2NA